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The  Joint  European  Society  of  Cardiology-American  College  of Cardiology  Foundation-American  Heart
Association-World  Heart  Federation  Task  Force  for  the  Redeﬁnition  of  Myocardial  Infarction  recommends
cardiac  troponin  (cTn)-T  as  a ﬁrst-line  biomarker,  and  suggests  the use  of  the 99th  percentile  of  a  reference
population  with  acceptable  precision  (i.e.  a coefﬁcient  of  variance  ≤10%)  as a cut-off  for  the  diagnosis  of
acute  myocardial  infarction.  Recently  developed  troponin  assays  fulﬁll  this  analytical  precision.  While
conventional  cTnT  assays  have  often  been  used  as  a positive  or negative  categorical  variable,  stepwise  risesroponin
atriuretic peptide
eart failure
ypertension
in  high  sensitivity  (Hs)-cTnT  in  patients  presenting  with  chronic  heart  failure  (HF)  have  been  associated
with  a progressive  increase  in  the  incidence  of cardiovascular  events.  Similar  observations  have  been
made  in  the general  population.  Hs-cTnT  at baseline  and  during  follow-up  is  a powerful  predictor  of
cardiac  events  in  patients  with  HF and  in the general  population.  Whether  it is  the ideal  biomarker  remains
to  be conﬁrmed,  however.  We  review  the  potential  contributions  of TnT  assays  in the assessment  of  risk
of HF,  in  HF,  and  in  myocardial  diseases  that  cause  HF.© 2012  Japanese  College  of Cardiology.  Published  by  Elsevier  Ltd.  All rights  reserved.
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ntroduction therapeutic intervention. As it relates to heart failure (HF), the ideal
biomarker should (1) be accurate in low serum concentrations,A biomarker is a characteristic that is objectively mea-
ured and evaluated as an indicator of normal biological
rocesses, pathogenic processes, or pharmacological responses to a
∗ Corresponding author at: Division of Cardiology, Hyogo Prefectural Amagasaki
ospital, Higashidaimotsucho 1-1-1, Amagasaki, Hyogo 660-0828 Japan.
el.: +81 06 6482 1521; fax: +81 06 6482 7430.
E-mail address: yukihito.sato@gmail.com (Y. Sato).
914-5087/$ – see front matter © 2012 Japanese College of Cardiology. Published by Else
ttp://dx.doi.org/10.1016/j.jjcc.2012.06.007(2) be practical when added to conventional diagnostic methods,
(3) have a prognostic value, and (4) predict cardiac events when
its concentration varies [1,2]. In the guidelines published by the
National Academy of Clinical Biochemistry Laboratory Medicine
Practice, measurements of B-type natriuretic peptide (BNP) and
amino N-terminal proB-type natriuretic peptide (NT-proBNP) in
the blood are both described as diagnostic markers and predic-
tors of risk in patients presenting with HF outside of the acute
phase of myocardial infarction (MI) [3].  On the other hand, the
vier Ltd. All rights reserved.
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ardiac troponin (cTn) assay was as a marker of MI.  The current Joint
uropean Society of Cardiology-American College of Cardiology
oundation-American Heart Association-World Heart Federation
ask Force for the Redeﬁnition of Myocardial Infarction recom-
ends measurements of cTn as a ﬁrst-line biomarker [4]. However,
levated cTn concentrations in the absence of myocardial dis-
ase, for instance after cardiac trauma, cardioversion, sepsis, and
ulmonary embolisms, have also been reported and reviewed else-
here [5–9]. We  review here the current clinical role of troponin
ssays in HF.
roponin assays
The three-unit troponin I, T, and C complex, located along with
ropomyosin on the actin ﬁlament, is essential for the calcium-
ediated regulation of skeletal and cardiac muscle contraction.
hile troponin T (37 kDa) and I (23 kDa) are both structural pro-
eins, 6–8% of cTnT and approximately 3.5% of cTnI are found in the
ytosole [7,8]. It has been hypothesized that, (a) during reversible
schemia, loss of membrane integrity causes the transient leakage
f cTn from the cytosolic component, and (b) when the ischemic
njury becomes irreversible, the release of troponin T or I becomes
ontinuous [7,8]. However, this hypothesis has not been veriﬁed
nd it remains controversial whether cTn can be released from
yocytes in the absence of cell death [10]. cTn is released from the
yocytes as ternary (cTnT–cTnI–TnC) or binary (cTnI–TnC) com-
lexes, or as free cTnT in patients with MI  [7,11].
While troponin C is not cardiac speciﬁc, and thus is not used for
he diagnosis of cardiac injury, cTnT and I are speciﬁc markers of
yocardial injury in acute coronary syndromes (ACS) [4].  Acute MI
s diagnosed by a rise and/or fall of cardiac biomarkers, with at least
ne measurement >99th percentile of the upper reference limit,
ogether with (a) symptoms, (b) electrocardiographic changes, or
c) imaging ﬁndings, consistent with myocardial ischemia. Impor-
antly, the professional guidelines recommend the use of the 99th
ercentile of a reference population with acceptable precision (i.e.
 coefﬁcient of variance ≤10%) as a cut-off value for the diagno-
is of acute MI.  However, until recently, the cTnT and cTnI assays
ere insufﬁciently precise to deﬁne reliably the 99th percentile of
 normal reference population. The delayed rise in circulating con-
entrations of cTn after initial patient presentation was  another
ajor limitation of conventional assays. These analytical weak-
esses have been successfully overcome by the development of
ewer assays. For example, the 99th percentile value of a healthy
eference population, using Roche Diagnostics’ (Basel, Switzerland)
igh-Sensitivity Troponin T assay, was 0.014 ng/ml, and the 10%
oefﬁcient of variability (CV) was 0.013 ng/ml [12]. With the
entaur® cTnI Ultra assay (Siemens, Munich, Germany), the 99th
ercentile of a healthy reference population was  0.04 ng/ml and
0% CV was 0.03 ng/ml [13].
Furthermore, the diagnostic performance of these new assays
f cTnT and I is high as early as upon presentation of the patients
n the emergency department, and allows the prediction of adverse
linical events [13–15].  The diagnostic performance of the troponin
ssay by areas under the receiver-operating-characteristic curves
n patients presenting within 3 h after the onset of chest pain was
.92 for the Roche high-sensitivity (Hs) and 0.76 for the standard
TnT assay (p = 0.005) [14].
Not only a diagnostic and short-term prognostic marker in
atients with acute MI,  cTn is also a predictor of long-term progno-
is in patients with stable coronary artery disease. Using a cut-off
alue of 0.01 g/l with the Beckman Access Accu TnI assay (Fuller-
on, CA, USA) (the 99th percentile of a healthy reference population
as 0.04 ng/ml and 10% CV was 0.06 ng/ml), the FRagmin and
ast Revascularization during InStability in Coronary artery dis-
ase II trial found that cTnI was a reliable, independent predictorlogy 60 (2012) 160–167 161
of mortality in patients stabilized after an episode of non-ST seg-
ment elevation ACS [16]. Furthermore, in the Prevention of Events
with Angiotensin Converting Enzyme Inhibition trial, concentra-
tions of Roche Hs-cTnT <99th percentile in a healthy population
were strongly associated with the incidence of cardiovascular death
and HF but not with MI  in patients presenting with stable coronary
artery disease [17]. This is in contrast with observation that ele-
vated cTn concentrations predict recurrent MI  more reliably than
HF events in patients with ACS [18]. The source of cTn release in
patients with chronic stable coronary artery disease needs to be
clariﬁed.
Finally, a new deﬁnition of Hs assay has recently been released.
Besides the CV analytical issue mentioned earlier, it includes
the requirement that measurable concentrations <99th percentile
value and above the assay’s limit of detection are ideally attainable
in >95% of healthy individuals [19].
Factors that inﬂuence the concentrations of troponin
In most studies, elevated cTnT concentrations have been asso-
ciated with increasing age, male gender, renal failure and left
ventricular (LV) hypertrophy in the general population [20–23].
However, Clerico et al. found age and male gender to be associ-
ated with elevated Siemens TnI Ultra concentrations in 692 healthy
subjects [24]. On the other hand, Eggers et al. reported no inﬂuence
by gender on the Beckman Access TnI [25]. Therefore, the clinical
characteristics that inﬂuence the concentrations of cTnT and cTnI
must be studied with each assay.
The mechanisms of cTnT or I elevation in patients with renal
insufﬁciency are also unresolved. They are often both elevated
in patients presenting with end-stage renal disease, even in the
absence of manifestations of myocardial ischemia. Apple et al.
reported an increase in mortality rate with changes in cTnT from
<0.01 ng/ml, to between >0.01 and 0.04 ng/ml, >0.04 and 0.1 ng/ml,
and >0.1 ng/ml in end-stage renal failure [26]. In a pooled analysis
of 28 studies, Khan et al. found that cTnT concentrations >0.1 ng/ml
were associated with a signiﬁcant increase in all-cause mortality
and a high risk of cardiac death in end-stage renal disease [27]. It
has been reported that current assays do not cross-react with iso-
forms expressed in skeletal muscle obtained from patients suffering
from end-stage renal disease [28] and hypothesized that the ele-
vated cTnT concentrations observed in end-stage renal disease are
unlikely to be false positive results. On the other hand, forms have
recently been found in diseased skeletal muscle that might increase
the concentrations of cTnT [29]. Furthermore, while it was  thought,
because of its relatively large molecular size, that cTnT is cleared by
the reticulo-endothelial system, it is fragmented into small enough
molecules to be cleared and excreted by the kidney [30,31]. There-
fore, the serum concentration of cTnT may  be partially determined
by renal clearance. However, it has also been suggested that the
clearance of cTnI is not changed by renal failure [32]. The results of
the measurements of cTn renal clearance might depend on which
of the epitopes that are detected by individual assays and by the
degradation of troponin.
Finally, there are hour-to-hour and week-to-week biological
variations in both cTnT [33] and cTnI [34] assays. While these
biological variations do not inﬂuence the interpretation of high
cTn concentrations measured in acute MI, they are important to
interpret the small serial changes in Hs-cTnT or I concentrations
observed in the absence of acute MI.Mechanisms of troponin elevation in heart failure
Although the mechanisms of troponin release in patients with
HF remain unclear, several studies in vitro have yielded some clues.
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n isolated rat hearts, an increased ventricular preload causes a
egradation of cTn independently of myocardial ischemia [35].
n increased myocardial wall stress and LV end-diastolic pressure
ight decrease the subendocardial perfusion, and increase the con-
entration of cTn. In concentrations measured in the failing heart,
orepinephrine caused necrosis of the myocytes [36]. Renin might
lso cause myocyte injury via the renin–angiotensin system, since
ngiotensin II causes the necrosis [37] and apoptosis of neona-
al and adult ventricular myocytes [38]. Likewise, tumor necrosis
actor-, an inﬂammatory cytokine, causes myocyte apoptosis [39].
inally, stretch due to myocardial overload can induce myocyte
ecrosis and apoptosis [40]. Recent studies have shown that the
ardiomyocytes can release cTn by a stretch-related mechanism
ediated by integrin [41]. In congestive HF, these pathophysiolog-
cal changes are all putative causes of myocyte injury [42], which,
n turn, further activates these mediators.
Despite these experimental observations, few human stud-
es have directly compared the concentrations of cTnT or I with
athogenic molecules. Horwich et al. [43] and Eggers et al. [25]
bserved correlations between elevated serum concentrations of
TnT and I, and an elevated pulmonary capillary wedge pressure.
ur group [44] and Latini et al. [45] found correlations between
levated serum concentrations of cTnT and elevated serum con-
entrations of BNP, renin, norepinephrine, and C-reactive protein.
hese observations suggest that myocardial load, activation of the
enin–angiotensin–aldosterone and of the sympathetic nervous
ystem, and inﬂammation, are causes of myocyte injury in patients
ith chronic HF. However, relationships between (a) apoptosis or
ecrosis and (b) cTn serum concentrations, remain to be shown.
In our study, patients presenting with acutely decompensated
AD) HF and increased cTnI concentrations despite treatment had
 signiﬁcantly lower blood pressure on admission and received
ore inotropes [46]. An analysis of the Acute Decompensated
eart Failure National (ADHERE) Registry also showed that patients
hose cTn concentrations were elevated had a lower mean sys-
olic blood pressure on admission, and patients with elevated cTnT
reated with inotropes had the highest in-hospital mortality [47].
herefore, a low myocardial perfusion resulting from low blood
ressure may  cause subendocardial ischemia due to a mismatch
etween myocardial oxygen supply and demand, and exogenous
notropes administered to maintain blood pressure and organ per-
usion, might also promote the loss of myocytes in patients with
DHF [48,49].  Despite the organ protective effects of natriuretic
eptides observed in vitro [50] neither carperitide (a recombinant
-human atrial natriuretic peptide) [51] nor nesiritide (BNP) [52]
owered the serial concentrations of cTn in patients presenting with
DHF.
Finally, the interpretation of elevated cTnT and I in patients
resenting with ischemic heart disease is somewhat problem-
tic. Patients with HF may  have asymptomatic stenoses of one
r more large or small coronary arteries. Therefore, the elevation
f biochemical markers of myocyte injury observed in patients
resenting with chronic HF and coronary stenoses may  be a con-
equence of ischemia of the myocardium supplied by the stenosed
rtery. However, in the Val-HeFT trial, an ischemic etiology was
resent in 60% and 57% of patients with versus without elevation
f cTnT, respectively, by conventional assay, versus 59% and 55%
f patients, respectively, using the Hs-cTnT assay [45]. Moreover,
n patients with acutely decompensated HF, the ADHERE Registry
howed that “ischemic heart failure” was the cause of acute cardiac
ecompensation in 53% and 52% of patients with versus with-
ut elevated cTn, respectively, and concluded that the presence of
nderlying ischemic heart disease was not a major discriminator
f cTn elevation [47]. Thus, an ischemic substrate does not seem to
e a major cause of cTn increase in patients with both chronic and
cute HF.logy 60 (2012) 160–167
Troponin and risk stratiﬁcation in heart failure
In 1997, Missov et al. reported a signiﬁcant elevation of cTnI in
advanced HF [53], and we reported that elevated cTnT and pro-
collagens are prognostic markers in patients with chronic HF [54].
We later reported that patients presenting with dilated cardiomy-
opathy and serum concentrations of cTnT persistently ≥0.02 ng/ml
during follow-up had higher rates of long-term adverse outcomes
and developed cardiac remodeling [55]. On the basis of these
observations, we  hypothesized that cTnT is a marker of subclinical
myocyte injury. Since then, several reports have been published
pertaining to the use of cTnT or I in the risk stratiﬁcation of
patients with congestive HF of ischemic or non-ischemic origin
[43,45,56–59] although the concentrations of cTn in HF are gen-
erally lower than in patients presenting with acute MI. Latini
et al. reported that in 4053 patients with chronic HF enrolled in
the Valsartan Heart Failure Trial (Val-HeFT), a cTnT concentra-
tion ≥0.01 ng/ml (median = 0.027 ng/ml) was detectable in 10.4%
of patients, compared with a ≥0.001 ng/ml concentration (median
of 0.012 ng/ml) in 92.0% of patients, using the Roche Hs-cTnT assay
[45]. In contrast to the conventional cTnT assay, often described
as a positive or negative categorical variable, these authors ﬁrst
reported the prognostic signiﬁcance of the Roche Hs-cTnT assay as
a continuous variable in patients with chronic HF. It is noteworthy
that when hazard ratios for mortality were plotted by increasing
deciles of the Roche Hs-cTnT concentrations at baseline, the risk of
death increased progressively.
Since HF is a complex clinical syndrome, a single biomarker
might not reﬂect all of its characteristics. BNP is a peptide chieﬂy
secreted by the ventricular myocardium in response to strain, and
the serum concentrations of BNP and NT-proBNP are being used
increasingly in the diagnosis and prognosis of HF [3].  BNP and NT-
proBNP may  be viewed as markers of myocardial load and cTnT and
cTnI as markers of myocyte injury [60]. Combining these biochem-
ical markers may  provide new insight in the management of HF
and reports support the additional prognostic value of cTnT or cTnI
with BNP or NT-proBNP [43,56,57,59]. In a study of 238 patients
with advanced HF referred for cardiac transplantation, BNP and
cTnI provided independent prognostic information and the com-
bination of increased BNP and increased cTnI identiﬁed patients
with a 12-fold increase in risk of death [43].
cTn is also a prognostic factor in patients with ADHF without
ACS [47,61–65].  The largest set of data has been collected by the
ADHERE Registry [47,65]. Although that registry included several
different cTnI assays with different cut-off points, Fonarow et al.
showed that BNP and cTnT or I on admission to the hospital are
signiﬁcant independent predictors of in-hospital mortality and, in
over 42,500 admissions for management of HF, elevations of both
BNP and cTnT or cTnI were associated with the highest risk of death
[65]. Peacock et al. measured the in-hospital mortality in >61,000
patients included in ADHERE, divided in quartiles of cTnT con-
centrations between ≤0.01 and >0.06 ng/ml, and quartiles of cTnI
between ≤0.04 and >0.20 ng/ml, and found a correlation (adjusted
odds ratio for death in the group of patients with a positive troponin
test: 2.55; 95% conﬁdence interval, 2.24–2.89; p < 0.001) between
cTn concentrations and prognosis [47].
Serial measurements of troponins in heart failure
The cTn concentrations measured during long-term follow-
up are equally powerful prognostic markers. The Val-HeFT study
showed that baseline and 4-month Hs-cTnT were both inde-
pendently correlated with mortality [45], and the same authors
reported recently that very small changes in Hs-cTnT over time are
predictors of cardiovascular events in patients with HF enrolled in
Y. Sato et al. / Journal of Cardio
Fig. 1. Concentrations of B-type natriuretic peptide (BNP) and cardiac Mitsubishi
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ardiomyopathy. BNP and cTnI both increased rapidly from the compensated to the
ecompensated phase of heart failure [48].
al-HeFT and GISSI-HF [66]. These observations suggest that serial
easurements of cTnT may  be of clinical relevance for the manage-
ent of chronic HF. With a conventional assay, Miller et al. reported
hat a decrease in cTnT concentrations to normal values was  asso-
iated with a decrease in risks of death or cardiac transplantation,
hereas a normalization of BNP concentrations did not change
hese risks [67,68].  Even small elevations of cTnT concentrations
ight be an indication for more aggressive treatment.
In 2002, we reported that a persistent elevation of cTnT despite
 decrease in BNP was a marker of poor prognosis in patients with
DHF [61]. However, serial measurements of cTn in these patients
re challenging because (1) the onset of acute cardiac decompen-
ation might be difﬁcult to detect, and (2) increases or decreases
n cTn concentrations are modest when compared with acute MI,
equiring a highly accurate assay at low concentrations. Using the
itsubishi (Tokyo, Japan) PATHFAST cTnI assay, we observed not
nly elevated BNP, but also cTnI in decompensated HF (Fig. 1)
48] and we observed poor outcomes in patients presenting with
cute cardiac decompensation, in whom the concentration of cTnI
ncreased on day 1 after hospital admission, despite treatment for
ecompensated HF and a decrease in the serum concentrations
f BNP [46]. Increases in cTn concentrations despite treatment of
DHF have been reported by others [62,69,70].  Biolo et al. recently
eported an elevation of the Siemens Centaur Ultra cTnI concen-
rations despite a decrease in NT-proBNP in patients with ADHF
eing discharged from the hospital. When compared with stable
F, concentrations of cTnI in patients with ADHF were twice as
igh [69]. Xue et al. reported that an elevation of Nanosphere
TnI after the initiation of therapy is a marker of poor prognosis
70].
Serial measurements are also important to predict cardiac
emodeling [71–73].  We  reported that cTnT at follow-up, but not
pon admission to the hospital, is a predictor of cardiac remod-
ling [71]. In the REVE-2 study, Fertin et al. recently observed that
TnI at baseline was not an independent predictor of LV remodeling,
hereas persistently elevated Siemens Advia Centaur cTnI concen-
rations during follow-up predicted LV remodeling after acute MI
73].
roponin in the assessment of the risk stage of heart failure
The prevalence of cTn elevation, and the prognostic value of cTn
n the general population has been recently reported [20–23].  In
 population-based sample of 3557 subjects enrolled in the Dal-
as Heart Study, the prevalence of cTnT elevation was 0.7% among
articipants without congestive HF, LV hypertrophy, chronic kid-
ey disease, or diabetes mellitus [20]. The authors suggested that
he merits of cTnT measurements as a cardiovascular screening test
eserve further study. de Lemos et al. reported that a concentrationlogy 60 (2012) 160–167 163
>0.003 ng/ml was  detectable by Hs-cTnT assay in 25% of the nearly
3500 subjects enrolled in the Dallas Heart Study, versus 0.7% by the
conventional cTnT assay [23]. Hs-cTnT >0.003 ng/ml was associ-
ated with male sex, older age, black race, history of HF, lower renal
function, and a greater LV mass. We  measured concentrations of
Hs-cTnT ≥0.003 ng/ml (mean = 0.008 ng/ml) in 80% of patients suf-
fering from essential hypertension [74]. Age, renal function, and LV
hypertrophy on electrocardiogram were independently associated
with elevated Hs-cTnT.
Minimally elevated serum cTn concentrations in the general
population have also been found to predict coronary events, HF,
and cardiac death. In 2006, Zethelius et al. reported that elevated
Beckman Accu cTnI concentrations in 70-year-old men free from
clinical manifestations of cardiovascular disease were associated
with an increased risk of death and ﬁrst coronary event in the
next 10 years [75]. These authors hypothesized that subclinical
myocyte injury precedes the development of HF, and reported
that elevated Beckman Accu cTnI concentrations are an indepen-
dent predictor of HF in 70-year-old men  without HF [76]. The
Atherosclerosis Risk in Communities reported that a Hs-cTnT con-
centration ≥0.003 ng/ml in a general population was associated
with an increased risk of coronary heart disease, mortality and hos-
pitalization for HF [77]. It is noteworthy that the hazard ratio of
a Hs-cTnT ≥0.003 ng/ml was  2.29 for coronary heart disease and
5.95 for HF, and that, in the general population, mildly elevated
concentrations of Hs-cTnT seem to be a predictor of HF rather
than a predictor of coronary events. The Cardiovascular Health
Study enrolled adults ≥65 years of age, without history of HF,
who underwent measurements of Hs-cTnT, at baseline and 2–3
years later [78]. The baseline cTnT concentrations and subsequent
changes were correlated with incident HF and cardiovascular death.
The patients with the highest baseline concentrations of Hs-cTnT
were at highest risk of experiencing subsequent cardiovascular
events [23,77,78].  Although several survival analyses have revealed
a stepwise increase in cardiac events at Hs-cTnT concentrations
≥0.003 ng/ml [23,77,78],  further studies are needed to identify the
optimal threshold of cTn concentrations in the population at risk
of HF.
Other myocardial diseases
Hypertrophic cardiomyopathy
Few reports have examined the signiﬁcance of cTn in patients
presenting with hypertrophic cardiomyopathy (HCM). In 2003, we
reported increased cTnT concentrations in 50% of patients suffering
from HCM in its non-dilated phase [79]. Most of these patients had
increased cTnT concentrations, which persisted over several years,
and fractional shortening and intraventricular septum thickness
decreased signiﬁcantly during follow-up, indicating that cTnT is a
marker of myocyte injury in these patients. Moreno et al. measured
serum concentrations of Hs-cTnT >0.014 ng/ml in 42% of 95 patients
with HCM. The elevated Hs-cTnT concentrations correlated posi-
tively with maximum LV wall thickness, left atrial diameter, and LV
outﬂow tract gradient [80]. Kubo et al. reported that elevated cTnI
was associated with (a) LV wall thickness, (b) peak early transmi-
tral ﬁlling velocity/peak early diastolic mitral annulus velocity on
tissue Doppler imaging, and (c) male gender in 162 patients suf-
fering from HCM [81]. The same authors observed, in 167 patients,
that cTnI was  a prognostic marker of HCM-related death, hospital-
ization for management of HF and stroke, and that the combined
measurements of cTnI and BNP further increased the prognos-
tic accuracy [82]. Cambronero et al. suggested that cTn is one
of the biomarkers in HCM from a pathophysiological perspective
[83].
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Fig. 2. Elevation of cardiac troponin (cTn) in various stages of heart diseases. HT,64 Y. Sato et al. / Journal of 
yocarditis
Myocarditis is most often caused by a virus, and less often by
n autoimmune reaction, hypereosinophilic syndrome or sarcoido-
is [84]. Besides acute MI,  severe myocarditis is often diagnosed
n patients presenting to the emergency room with acute chest
ain and elevated cTn, who usually undergo coronary angiography
o rule out MI  [85,86].  In the absence of coronary artery disease,
he endomyocardium is biopsied with a view to make a diagnosis.
lthough the pathophysiology of cTn release in patients present-
ng with myocarditis has not been clariﬁed, myocyte death and
schemia due to vasospasm seem likely causes of elevated cTn [84].
owever, at the present time, the diagnostic importance of cTn in
yocarditis has not been elucidated.
From a therapeutic perspective, some studies, including our
wn, have observed a decrease in the serum concentrations of cTn
fter successful immunosuppressive therapy in patients with viral
yocarditis [87] or eosinophilic myocarditis [88], and after inter-
eron therapy in patients with viral myocarditis [89]. While the
igniﬁcance of Hs-cTn assay has not been clariﬁed, it might be useful
s a therapeutic monitoring tool in the management of myocarditis.
ardiac amyloidosis
Light chain amyloidosis is a plasma cell dyscrasia characterized
y the extracellular deposition of pathologic, insoluble, -ﬁbrillar
mmunoglobulin light chain in several organs. Cardiac involve-
ent is the most important determinant of the clinical outcome.
n 2003, Dispenzieri et al. reported that cTnT, cTnI, septal thick-
ess, LV ejection fraction, urine M-spike, age, and clinical symptoms
f congestive HF were correlated with overall survival, and that
etectable cTnT was the strongest predictor of overall survival by
ultiple variable analysis [90]. With a dedicated assay, it has been
eported that even slightly increased serum concentrations of Hs-
TnT might indicate cardiac involvement that remains undetected
y echocardiography or electrocardiography, and the outcome
f patients with Hs-cTnT >0.05 ng/ml has been associated with
dverse outcomes [91]. Besides a single report of serial measure-
ents of cTn in 5 patients suffering from light chain amyloidosis
92], Palladini et al., who studied 171 consecutive patients with the
isease, found that Hs-cTnT at baseline was a predictor of survival,
nd that a >75% increase in Hs-cTnT after treatment predicted poor
utcomes [93].
hemotherapy
Chemotherapy is administered for several types of cancers.
owever, its clinical efﬁcacy is often limited by cardiotoxicity,
hich causes LV dysfunction and HF. Cardinale et al. reported
hat cTnI early after high-dose chemotherapy predicts a decrease
n LVEF [94], and that persistently elevated concentrations of
TnI predict adverse cardiac events [95]. However, since most
eaths in patients suffering from cancer are not cardiac, most
tudies examined the relationship between serum cTn concen-
rations and changes in echocardiographic LVEF [96,97]. Sawaya
t al. reported that Hs-cTnI measurements (Siemens Healthcare
iagnostics) made after 3 months of chemotherapy independently
redicted the changes in LVEF observed at 6 months [98]. It is
oteworthy that most patients in whom cTn remained persistently
ndetectable did not develop echocardiographic deterioration of
V function.erspectives
HF develops from risk factors ranging from LV hypertrophy and
I,  to cardiac remodeling and HF. Troponin measurements of allhypertension; AMI, acute myocardial infarction.
these stages have been discussed in recent articles (Fig. 2) and
stepwise elevation is seen from hypertension to acute HF (Fig. 3).
Therefore, cTn is a promising, clinically applicable biomarker. While
the deﬁnition and practice guidelines for MI  suggest that the cut-off
cTn serum concentration is the 99th percentile of a normal refer-
ence population [4],  individuals, whether in the general population
or suffering from essential hypertension, whose serum Hs-cTnT
concentration is <99th percentile may  have structural abnormal-
ities, such as myocardial hypertrophy [22,23,74],  and may  have a
poor prognosis [22,23,77,78].  The 99th percentile in healthy sub-
jects may  also be inﬂuenced by gender and age [24,25]. Therefore,
the deﬁnition of the 99th percentile might be derived from a
younger healthy population, while the cut-off value for HF and the
general population remains to be determined.
Serial measurements have shown that cTn at baseline and cTn
at follow-up are powerful predictors of cardiac remodeling and
adverse cardiac events [55,71,73].  Whether cTn can be used as a
surrogate marker of HF [2] needs to be studied further. Whether
aggressive treatments that attenuate the rises in cTn improve the
clinical outcomes should also be studied. Finally, although Tn assays
have been developed for humans, some cross-reactivity has been
reported, which allow their application in animal models [99,100].
These animal studies may elucidate the pathophysiology of heart
failure based on Tn assay.Fig. 3. High sensitive troponin (Hs-Tn)T (Roche Diagnostics) concentrations in
patients with hypertension (0.009 ± 0.005 ng/ml, n = 98), chronic heart failure
(0.015 ± 0.015 ng/ml, n = 93), and acute heart failure (0.035 ± 0.033 ng/ml, n = 91)
(unpublished data). Stepwise elevation of Hs-TnT is seen.
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